Ipamorelin is a synthetic growth hormone releasing peptide (GHRP) that stimulates the pituitary gland to secrete growth hormone without affecting other hormones such as cortisol or prolactin. Its structure, a hexapeptide with the sequence His-D-Ala-Lys-Pro-Gly-Trp-NH₂, gives it high selectivity and stability in circulation. Clinically, Ipamorelin is used for muscle repair, anti-aging therapies, and weight management, while research laboratories employ it to study growth hormone dynamics.
**Product information**
The 5 mg vial of Ipamorelin sold in Canada is formulated as a sterile peptide solution suitable for subcutaneous injection. Each vial contains a precisely weighed dose that has been dissolved in an isotonic buffer, ensuring consistent bioavailability. The product adheres to Canadian pharmaceutical standards and carries the necessary regulatory approvals for clinical use or research purposes.
**Certificate of Analysis**
A Certificate of Analysis accompanies each batch, providing detailed assay results. Key parameters include:
- **Purity:** ≥ 99 % as verified by high-performance liquid chromatography (HPLC).
- **Identity:** Confirmed through mass spectrometry and amino acid sequencing.
- **Potency:** Demonstrated via in-vitro GH release assays.
- **Microbial Limits:** Tested for sterility, endotoxins, and residual solvents, all within acceptable limits.
These data give healthcare providers confidence that the peptide meets stringent quality criteria before administration.
**About Mannitol**
Mannitol is a common excipient used in peptide preparations to enhance solubility and stabilize the molecule during storage. In Ipamorelin vials, mannitol acts as a cryoprotectant, preventing aggregation when the solution is frozen or thawed. It also contributes to isotonicity, reducing irritation at injection sites. The concentration of mannitol in this product is carefully controlled to avoid any osmotic imbalance.
**Vial specifications**
- **Volume:** 5 mL total, containing a 1 mg/mL concentration of Ipamorelin.
- **Material:** Glass vials with screw-top caps and pre-filled syringes for precise dosing.
- **Sterility:** Single-use, autoclaved containers that maintain sterility until first use.
- **Storage Conditions:** Recommended at 2–8 °C; protected from light to preserve peptide integrity.
These specifications ensure that each dose remains accurate and free from contamination throughout its shelf life.
**Reviews**
Users of the Canadian Ipamorelin 5 mg vial report high satisfaction with product consistency and ease of use. Many note rapid onset of action in muscle recovery protocols, attributing this to the stringent purity controls highlighted in the Certificate of Analysis. Some reviewers emphasize the minimal side-effect profile, likely due to the peptide’s selective growth hormone release mechanism. Overall feedback underscores the reliability of the formulation for both clinical applications and research studies.
**Ipamorelin**
Ipamorelin is a synthetic growth hormone releasing peptide (GHRP) that stimulates the pituitary gland to secrete growth hormone without affecting other hormones such as cortisol or prolactin. Its structure, a hexapeptide with the sequence His-D-Ala-Lys-Pro-Gly-Trp-NH₂, gives it high selectivity and stability in circulation. Clinically, Ipamorelin is used for muscle repair, anti-aging therapies, and weight management, while research laboratories employ it to study growth hormone dynamics.
**Product information**
The 5 mg vial of Ipamorelin sold in Canada is formulated as a sterile peptide solution suitable for subcutaneous injection. Each vial contains a precisely weighed dose that has been dissolved in an isotonic buffer, ensuring consistent bioavailability. The product adheres to Canadian pharmaceutical standards and carries the necessary regulatory approvals for clinical use or research purposes.
**Certificate of Analysis**
A Certificate of Analysis accompanies each batch, providing detailed assay results. Key parameters include:
- **Purity:** ≥ 99 % as verified by high-performance liquid chromatography (HPLC).
- **Identity:** Confirmed through mass spectrometry and amino acid sequencing.
- **Potency:** Demonstrated via in-vitro GH release assays.
- **Microbial Limits:** Tested for sterility, endotoxins, and residual solvents, all within acceptable limits.
These data give healthcare providers confidence that the peptide meets stringent quality criteria before administration.
**About Mannitol**
Mannitol is a common excipient used in peptide preparations to enhance solubility and stabilize the molecule during storage. In Ipamorelin vials, mannitol acts as a cryoprotectant, preventing aggregation when the solution is frozen or thawed. It also contributes to isotonicity, reducing irritation at injection sites. The concentration of mannitol in this product is carefully controlled to avoid any osmotic imbalance.
**Vial specifications**
- **Volume:** 5 mL total, containing a 1 mg/mL concentration of Ipamorelin.
- **Material:** Glass vials with screw-top caps and pre-filled syringes for precise dosing.
- **Sterility:** Single-use, autoclaved containers that maintain sterility until first use.
- **Storage Conditions:** Recommended at 2–8 °C; protected from light to preserve peptide integrity.
These specifications ensure that each dose remains accurate and free from contamination throughout its shelf life.
**Reviews**
Users of the Canadian Ipamorelin 5 mg vial report high satisfaction with product consistency and ease of use. Many note rapid onset of action in muscle recovery protocols, attributing this to the stringent purity controls highlighted in the Certificate of Analysis. Some reviewers emphasize the minimal side-effect profile, likely due to the peptide’s selective growth hormone release mechanism. Overall feedback underscores the reliability of the formulation for both clinical applications and research studies.